License Agreements - Harvard License Agreement - Additional Information (Details) - Harvard |
12 Months Ended | ||
|---|---|---|---|
|
Jun. 10, 2021
shares
|
Dec. 31, 2023
USD ($)
|
May 31, 2021
USD ($)
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success payment amount due | $ 15,000,000 | ||
| Issuance of common stock for success payment liability, Shares | shares | 174,825 | ||
| Minimum | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success payments | $ 5,000,000 | ||
| Minimum | Series A Preferred Stock | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success Payments, valuation multiples | 5 | ||
| Maximum | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Additional success payment amount due | $ 90,000,000 | ||
| Success payments | $ 105,000,000 | ||
| Maximum | Series A Preferred Stock | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success Payments, valuation multiples | 40 | ||
| Success Payments | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Agreement description | The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period, commencing one year after the Company’s IPO. | ||
| Other Payments | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Agreement description | The Company agreed to pay Harvard an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $75.9 million in product development and regulatory approval milestones, or Harvard Product Milestones. If the Company completes a change of control during the term of the Harvard License Agreement, then certain of the milestone payments would be increased. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Harvard License Agreement to a third party and the Company receives non-royalty sublicense income, then Harvard is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company’s licensed products at such time. | ||
| Product Development and Regulatory Approval | Maximum | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Aggregate milestone amount | $ 75,900,000 |